| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | 0 |
Sells | $1,134,584 | 18 | 100 |
| Yaffe Kristine | director | 0 | $0 | 1 | $25,309 | $-25,309 |
| Hammond Paula | director | 0 | $0 | 1 | $53,179 | $-53,179 |
| Romano Gary | Chief Medical Officer | 0 | $0 | 3 | $102,832 | $-102,832 |
| GRASSO MARC | Chief Financial Officer | 0 | $0 | 4 | $125,777 | $-125,777 |
| Kenkare-Mitra Sara | President and Head of R&D | 0 | $0 | 4 | $209,381 | $-209,381 |
| SCHELLER RICHARD H | director | 0 | $0 | 1 | $228,388 | $-228,388 |
| Rosenthal Arnon | Chief Executive Officer | 0 | $0 | 4 | $389,718 | $-389,718 |
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at Alector, Inc. have bought $0 and sold $1.13M worth of Alector, Inc. stock.
On average, over the past 5 years, insiders at Alector, Inc. have bought $0 and sold $11.02M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 40,000 shares for transaction amount of $1M was made by Wehner David M. (director) on 2020‑02‑03.
| 2025-06-02 | Sale | Rosenthal Arnon | Chief Executive Officer | 52,087 0.0505% | $1.34 | $69,713 | +12.64% | |
| 2025-06-02 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 23,890 0.0232% | $1.34 | $31,974 | +12.64% | |
| 2025-06-02 | Sale | GRASSO MARC | Chief Financial Officer | 16,488 0.016% | $1.34 | $22,068 | +12.64% | |
| 2025-03-03 | Sale | Rosenthal Arnon | Chief Executive Officer | 40,330 0.0419% | $1.47 | $59,176 | -8.51% | |
| 2025-03-03 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 29,073 0.0302% | $1.47 | $42,662 | -8.51% | |
| 2025-03-03 | Sale | Romano Gary | Chief Medical Officer | 16,306 0.0169% | $1.47 | $23,927 | -8.51% | |
| 2025-03-03 | Sale | GRASSO MARC | Chief Financial Officer | 18,091 0.0188% | $1.47 | $26,547 | -8.51% | |
| 2024-12-02 | Sale | Rosenthal Arnon | Chief Executive Officer | 52,172 0.0534% | $2.52 | $131,442 | -39.04% | |
| 2024-12-02 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 26,500 0.0271% | $2.52 | $66,764 | -39.04% | |
| 2024-12-02 | Sale | Romano Gary | Chief Medical Officer | 14,892 0.0152% | $2.52 | $37,519 | -39.04% | |
| 2024-12-02 | Sale | GRASSO MARC | Chief Financial Officer | 16,489 0.0169% | $2.52 | $41,542 | -39.04% | |
| 2024-09-03 | Sale | Rosenthal Arnon | Chief Executive Officer | 26,499 0.0282% | $4.88 | $129,387 | -62.61% | |
| 2024-09-03 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 13,926 0.0148% | $4.88 | $67,981 | -62.61% | |
| 2024-09-03 | Sale | Romano Gary | Chief Medical Officer | 8,478 0.009% | $4.88 | $41,385 | -62.61% | |
| 2024-09-03 | Sale | GRASSO MARC | Chief Financial Officer | 7,297 0.0078% | $4.88 | $35,620 | -62.61% | |
| 2024-08-22 | Sale | SCHELLER RICHARD H | director | 44,250 0.0463% | $5.16 | $228,388 | -64.89% | |
| 2024-08-12 | Sale | Yaffe Kristine | director | 5,000 0.0051% | $5.06 | $25,309 | -64.97% | |
| 2024-08-12 | Sale | Hammond Paula | director | 10,500 0.0108% | $5.06 | $53,179 | -64.97% | |
| 2024-06-03 | Sale | Rosenthal Arnon | Chief Executive Officer | 25,135 0.0249% | $4.80 | $120,618 | -49.60% | |
| 2024-06-03 | Sale | Kenkare-Mitra Sara | President and Head of R&D | 13,206 0.0131% | $4.80 | $63,373 | -49.60% |
| Rosenthal Arnon | Chief Executive Officer | 2414657 2.4148% | $3.53M | 0 | 21 | |
| Kenkare-Mitra Sara | President and Head of R&D | 512252 0.5123% | $747,887.92 | 0 | 10 | |
| Romano Gary | Chief Medical Officer | 332977 0.333% | $486,146.42 | 0 | 11 | |
| GRASSO MARC | Chief Financial Officer | 296072 0.2961% | $432,265.12 | 0 | 10 | |
| Yaffe Kristine | director | 67709 0.0677% | $98,855.14 | 0 | 1 | |
| Hammond Paula | director | 60209 0.0602% | $87,905.14 | 0 | 1 | |
| SCHELLER RICHARD H | director | 35000 0.035% | $51,100.00 | 0 | 4 | |
| MCGUIRE TERRANCE | 10853817 10.8546% | $15.85M | 0 | 2 | ||
| Polaris Venture Management Co. VI, L.L.C. | 10 percent owner | 10853817 10.8546% | $15.85M | 0 | 2 | |
| GORDON CARL L | 10434976 10.4357% | $15.24M | 1 | 0 | +10.01% | |
| ORBIMED ADVISORS LLC | 10 percent owner | 1906718 1.9069% | $2.78M | 1 | 17 | +10.01% |
| Oney Sabah | Chief Business Officer | 573918 0.574% | $837,920.28 | 0 | 11 | |
| King Robert | Chief Development Officer | 529295 0.5293% | $772,770.70 | 0 | 11 | |
| Paul Robert | Chief Medical Officer | 234319 0.2343% | $342,105.74 | 0 | 37 | |
| SULIMAN SHEHNAAZ | President and COO | 102598 0.1026% | $149,793.08 | 0 | 4 | |
| Yu Calvin | Vice President, Finance | 76686 0.0767% | $111,961.56 | 0 | 8 | |
| Wehner David M. | director | 44621 0.0446% | $65,146.66 | 1 | 0 | <0.0001% |
$7,224,762 | 91 | -8.21% | $168.19M | |
$11,468,215 | 44 | 17.78% | $163.81M | |
$16,259,194 | 41 | 120.51% | $140.18M | |
$63,049,419 | 31 | 2.87% | $126.16M | |
$2,747,487 | 21 | -19.10% | $168.04M | |
$294,424,120 | 20 | 1.33% | $138.71M | |
$1,239,833 | 16 | 53.23% | $130.91M | |
$178,593,887 | 15 | -14.86% | $132.49M | |
$448,999,793 | 15 | -19.99% | $129.14M | |
$15,799,576 | 12 | -39.47% | $166.47M | |
$10,143,329 | 12 | 11.84% | $154.55M | |
$145,296,407 | 8 | -0.98% | $168.22M | |
$22,090,972 | 7 | -3.49% | $164.38M | |
$63,981 | 5 | -11.55% | $126.38M | |
Alector, Inc. (ALEC) | $32,289,200 | 3 | -5.46% | $145.99M |
$40,000,000 | 3 | -16.24% | $168.65M | |
$149,309 | 3 | 6.07% | $168.02M | |
$9,999,990 | 2 | 25.53% | $140.76M | |
$300,016 | 1 | -50.33% | $141.86M |
| Increased Positions | 67 | +40.12% | 4M | +5.96% |
| Decreased Positions | 63 | -37.72% | 5M | -6.89% |
| New Positions | 23 | New | 1M | New |
| Sold Out Positions | 28 | Sold Out | 1M | Sold Out |
| Total Postitions | 171 | +2.4% | 73M | -0.93% |
| Fmr Llc | $19,097.00 | 14.69% | 14.69M | +94,851 | +0.65% | 2024-12-31 |
| Ra Capital Management, L.P. | $12,604.00 | 9.7% | 9.7M | +10M | New | 2024-12-31 |
| Blackrock, Inc. | $10,764.00 | 8.28% | 8.28M | -857,045 | -9.38% | 2025-03-31 |
| Vanguard Group Inc | $7,301.00 | 5.62% | 5.62M | +160,652 | +2.94% | 2024-12-31 |
| Merck & Co., Inc. | $4,609.00 | 3.55% | 3.55M | +4M | New | 2024-12-31 |
| Geode Capital Management, Llc | $2,489.00 | 1.91% | 1.91M | +10,308 | +0.54% | 2024-12-31 |
| State Street Corp | $2,404.00 | 1.85% | 1.85M | -767,514 | -29.33% | 2024-12-31 |
| Jpmorgan Chase & Co | $2,135.00 | 1.64% | 1.64M | -1M | -39.81% | 2024-12-31 |
| Euclidean Capital Llc | $1,700.00 | 1.31% | 1.31M | 0 | 0% | 2024-12-31 |
| Deutsche Bank Ag | $1,438.00 | 1.11% | 1.11M | -48,050 | -4.16% | 2024-12-31 |